Antipsychotic drugs and metabolic syndrome: can we prevent it?

Reis, André

doi:10.1590/s1516-44462007000100005

Cited by 4 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Collaboration between the psychiatric and diabetology or endocrinologist teams is essential to minimize the risk of diabetes and obesity in patients taking second generation antipsychotics. 26 Limitations of the present study are its relatively small sample size, lack of a control group and, as it was a naturalistic study, the treatment was not controlled. Sedentary lifestyle was not assessed during the study, and we know that this is an important factor on prevention of cardiovascular and metabolic diseases.…”

Section: Discussionmentioning

confidence: 91%

Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

Àttux

Quintana

Chaves

2007

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

Àttux

Quintana

Chaves

2007

Rev. Bras. Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…Consistent with the epidemiological data found in other cultural contexts [84,85], most of the participants offered examples of many cases encountered in their respective clinical practice scenarios of PWSMI with comorbid chronic physical conditions such as cardiovascular diseases and diabetes. Although research has argued that mental health medications and modifiable risk factors are largely responsible for their physical chronic conditions [2,86,87], psychosocial factors such as stigma have been traditionally overlooked. Our findings document how healthcare professional's stigmatizing attitudes and beliefs can directly impact their healthcare interventions.…”

Section: Discussionmentioning

confidence: 99%

“That’s all Fake”: Health professionals stigma and physical healthcare of people living with Serious Mental Illness

2019

View full text Add to dashboard Cite

Background People living with a Serious Mental Illness (SMI) die earlier than the general population due to preventable medical conditions. Latinos living with SMI are a particularly vulnerable population with higher prevalence of chronic medical conditions. Stigma has been identified as a factor that fosters health inequities for Latinos/as with SMI, particularly Puerto Ricans. Although personal and social consequences of stigmatization have been well documented, research regarding the role of cultural factors on healthcare interactions is scarce. Furthermore, little research has focused on addressing stigma from the perspective of healthcare professionals. Methods We investigated this process through a qualitative design using semi-structured individual interviews with 11 healthcare professionals (8 physicians and 3 nurses) in Puerto Rico. We conducted a thematic analysis to analyze the data. Results Following a thematic analysis, we found three main themes and nine sub-themes related to the stigmatization process. Some participants reported perceptions of dangerousness and uneasiness, social distance and inadequate care. Participants also emphasized a lack of medical training regarding SMI within the Puerto Rican context. Conclusions These findings support the need to develop culturally appropriate public health interventions targeting healthcare professionals in order to address stigma and eliminate health disparities among Latinos/as with SMI.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2007

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Antipsychotic drugs and metabolic syndrome: can we prevent it?

Cited by 4 publications

References 3 publications

Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up

“That’s all Fake”: Health professionals stigma and physical healthcare of people living with Serious Mental Illness

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About